Earnings call Viking Therapeutics reported a Q2 2026 net loss of $128.1M ($1.10/share), nearly doubling YoY due to sharply higher R&D and G&A expenses as phase III obesity trials advanced. Management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results